晚期非小细胞肺癌化疗联合免疫治疗进展

化疗在晚期非小细胞肺癌（non-small cell lung cancer，NSCLC）的治疗中发挥着重要的作用，但近年来免疫检查点抑制剂在晚期NSCLC的治疗中也表现出了良好的效果，因此两者联合治疗能否产生更佳的治疗效果成为了人们关注的焦点。本文综述总结了程序性死亡受体1（programmed death 1，PD-1/PD-L1）抑制剂、细胞毒性T淋巴细胞相关蛋白（cytotoxic T-lymphocyte-associat? ed protein 4，CTLA4）抑制剂等不同免疫治疗方案分别联合不同化疗方案治疗晚期NSCLC的疗效及安全性，并阐述联合治疗方案疗效增加可能的机制，同时对晚期NSCLC未来的治疗模式做出了展望。 

Progress in chemotherapy combined with immunotherapy for advanced non-small cell lung cancer

Chemotherapy plays an important role in the treatment of advanced non-small cell lung cancer (NSCLC). However, in recent years, immune checkpoint inhibitors have also been shown to have a good effect against advanced NSCLC. Whether the combination therapy can produce better results has become the focus of attention. This review summarizes the efficacy and safety of the use of death receptor 1 (programmed death 1, PD-1/PD-L1) inhibitors or cytotoxic T lymphocyte-associated protein (cytotoxic T lymphocyteassociated protein 4, CTLA4) inhibitors combined with chemotherapy for the treatment of NSCLC. This article also expounds the mechanisms of the combination therapy in enhancing curative effect, thereby providing insights into future treatment options for advanced non-small cell lung cancer.